AI in Oncology Market to Reach US$ 22.85 Billion by 2033 at 25.3% CAGR; North America Leads with 42% Share; Key Players Include Tempus, Paige AI, ConcertAI

The global AI in Oncology Market reached US$ 2.43 billion in 2024 and is expected to reach US$ 22.85 billion by 2033, growing at a CAGR of 25.3% during the forecast period 2025-2033. Market growth is driven by rapid advancements in artificial intelligence technologies, rising global cancer prevalence, and the increasing shift toward precision and personalized oncology care.

AI in oncology involves the use of machine learning, deep learning, and data analytics to support cancer diagnosis, treatment planning, drug discovery, and clinical decision-making. Healthcare providers and pharmaceutical companies are increasingly investing in AI-powered imaging analysis, predictive analytics, and therapy optimization platforms to improve diagnostic accuracy and treatment outcomes. Supportive regulatory frameworks, growing approvals of AI-based cancer detection solutions, and strong collaboration between healthcare institutions, technology providers, and research organizations are accelerating clinical adoption. North America currently dominates the market due to its advanced healthcare infrastructure, strong regulatory support, and high penetration of AI technologies, while continued innovation and expanding clinical applications are strengthening the long-term outlook of the global AI in oncology market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ai-in-oncology-market?sai-v

The AI in Oncology Market refers to the global industry focused on applying artificial intelligence technologies to improve cancer detection, diagnosis, treatment planning, and clinical decision-making.

Key Developments
✅ January 2026: In North America, leading cancer centers expanded use of AI-driven imaging and pathology platforms to improve early tumor detection and streamline treatment planning.

✅ December 2025: In Europe, oncology clinics increased deployment of AI-enabled predictive analytics for personalized therapy selection and outcome forecasting.

✅ November 2025: In Asia-Pacific, integration of AI algorithms with genomic and multi-omics data enhanced precision oncology workflows in major research hospitals.

✅ October 2025: In Latin America, cancer care networks adopted AI-assisted radiotherapy planning tools to improve dosimetry accuracy and reduce planning time.

✅ September 2025: In the Middle East, healthcare providers introduced AI-supported clinical decision support systems for multidisciplinary oncology teams.

✅ August 2025: In Africa, pilot programs evaluated AI-based screening tools to detect cervical and breast cancers at earlier stages in population health initiatives.

Mergers & Acquisitions
✅ January 2026: In North America, a prominent AI healthcare software company acquired an oncology analytics platform provider to strengthen its cancer care solutions.

✅ December 2025: In Europe, a digital health firm partnered with a major oncology technology developer through acquisition of IP assets to accelerate AI model development.

✅ November 2025: In Asia-Pacific, a regional medical technology group acquired an AI-based diagnostic imaging startup to enhance its oncology AI offerings.

Key Players
Azra AI | CureMetrix, Inc. | ConcertAI | Immunai | MVision AI Inc. | Paige AI, Inc. | Mindpeak GmbH | Imagene AI Ltd. | Predictive Oncology | Tempus

Key Highlights
Tempus - Holds 22.4% share, driven by strong adoption of AI-powered clinical decision support, large-scale multimodal oncology datasets, and deep integration with healthcare providers and research institutions.

Paige AI, Inc. - Holds 18.7% share, supported by FDA-cleared AI pathology solutions, strong partnerships with cancer centers, and growing deployment in digital pathology workflows.

ConcertAI - Holds 14.9% share, benefiting from real-world evidence platforms, advanced oncology analytics, and strong pharmaceutical and biotech collaborations.

Immunai - Holds 11.6% share, driven by AI-based single-cell and immuno-oncology analytics, accelerating biomarker discovery and precision medicine research.

CureMetrix, Inc. - Holds 9.3% share, supported by AI-enabled cancer detection imaging tools, particularly in breast oncology diagnostics.

Imagene AI Ltd. - Holds 7.5% share, leveraging computational pathology and biomarker prediction technologies to support precision oncology and treatment selection.

Predictive Oncology - Holds 6.0% share, focused on AI-driven tumor modeling, drug response prediction, and oncology data platforms for research and development.

Mindpeak GmbH - Holds 4.5% share, driven by AI-assisted pathology algorithms for cancer diagnosis and workflow automation in European healthcare systems.

MVision AI Inc. - Holds 3.2% share, specializing in AI-based radiation oncology contouring and treatment planning optimization.

Azra AI - Holds 1.9% share, contributing through AI-powered oncology workflow automation and clinical efficiency tools with emerging adoption.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ai-in-oncology-market?sai-v

Market Drivers
- Rising global cancer burden increasing demand for advanced diagnostic, treatment planning, and monitoring solutions.

- Growing adoption of AI-based imaging and pathology tools for early cancer detection and accurate diagnosis.

- Increasing need for personalized and precision oncology supported by AI-driven data analytics.

- Integration of AI in drug discovery, clinical decision support, and treatment optimization workflows.

- Expansion of digital healthcare infrastructure and availability of large oncology datasets.

Industry Developments
- Continuous innovation in AI-powered radiology, pathology, and genomic analysis platforms for oncology.

- Increasing use of machine learning algorithms to support clinical decision-making and therapy selection.

- Strategic collaborations between AI technology providers, pharmaceutical companies, and oncology centers.

- Rising investments in AI-based oncology startups and digital cancer care solutions.

- Regulatory progress and clinical validation supporting adoption of AI tools in oncology practice.

Regional Insights
North America - 42% share: "Driven by advanced cancer care infrastructure, high adoption of AI-enabled healthcare technologies, strong R&D investments, and early integration of AI in oncology workflows."

Europe - 25% share: "Supported by increasing use of AI in cancer screening programs, strong regulatory frameworks, and growing focus on precision medicine."

Asia Pacific - 26% share: "Fueled by rising cancer incidence, expanding healthcare digitization, increasing AI investments, and large patient data availability."

Latin America - 4% share: "Driven by gradual adoption of digital oncology solutions and improving access to advanced cancer diagnostics."

Middle East & Africa - 3% share: "Supported by healthcare infrastructure development, growing awareness of AI-driven cancer care, and increasing investments in digital health technologies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-oncology-market?sai-v

Key Segments

By Component Type
Software dominates the AI in oncology market, driven by widespread adoption of AI-powered platforms for imaging analysis, clinical decision support, and data analytics. Services hold a significant share, supported by growing demand for implementation, integration, training, and ongoing maintenance. Hardware contributes steadily through high-performance computing systems and imaging infrastructure required to support AI applications.

By Cancer Type
Breast cancer represents a major segment, driven by high incidence rates and strong adoption of AI in screening and imaging diagnostics. Lung cancer holds a substantial share, supported by increasing use of AI for early detection, risk stratification, and treatment planning. Prostate and colorectal cancers are gaining traction due to growing application of AI in pathology and precision oncology. Other cancers, including brain, skin, and hematological malignancies, contribute through expanding AI-driven research and clinical use.

By Application
Diagnosis and screening dominate the market, driven by extensive use of AI in medical imaging, pathology, and early cancer detection. Treatment planning and clinical decision support represent a significant segment, supported by personalized oncology and precision medicine approaches. Drug discovery and development are witnessing rapid growth, driven by AI-enabled target identification and clinical trial optimization. Other applications, including patient monitoring and workflow optimization, further support overall market expansion.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.